Literature DB >> 6149239

Effect of clozapine in severe tardive dyskinesia: a case report.

H Y Meltzer, D J Luchins.   

Abstract

There have been conflicting reports as to whether clozapine, an atypical antipsychotic, will suppress symptoms of tardive dyskinesia. With this in mind, the authors present the case of a 32-year-old chronically institutionalized schizophrenic who showed a remarkable improvement in both tardive dyskinesia and psychotic symptoms following an open trial of clozapine, 900 mg daily. This effect was noted to persist throughout the 15-month observation period with no breakthrough dyskinesia. The ability of clozapine to suppress tardive dyskinesia symptoms raises the possibility that clozapine, at least at the doses used in this report, might also induce the disorder. Long-term, controlled studies are required to specifically address this issue.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149239

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  15 in total

1.  Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia--a retrospective study of 387 patients.

Authors:  D Naber; M Leppig; R Grohmann; H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study.

Authors:  Itzhak Kimiagar; Evgenia Dobronevsky; Tatiana Prokhorov; Ala Miniovitz; Jose M Rabey
Journal:  J Neurol       Date:  2011-11-09       Impact factor: 4.849

4.  Clozapine in the treatment of 121 out-patients.

Authors:  M Leppig; B Bosch; D Naber; H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Tolerability of long term clozapine treatment.

Authors:  M Schmauss; R Wolff; A Erfurth; E Rüther
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Clozapine. Scientific update meeting. Montreux, Switzerland. October 31-November 1, 1988. Proceedings.

Authors: 
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.

Authors:  B L Roth; S Tandra; L H Burgess; D R Sibley; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

Review 8.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

9.  Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care.

Authors:  Raphael J. Leo; Paula Del Regno
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

Review 10.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.